Therapeutics News and Research

RSS

Laminin-111 shows potential for congenital muscular dystrophy

Current research suggests laminin, a protein that helps cells stick together, may lead to enhanced muscle repair in muscular dystrophy.

1 Jan 2009

Medication errors among adults and children with cancer in the outpatient setting common

Seven percent of adults and 19 percent of children taking chemotherapy drugs in outpatient clinics or at home were given the wrong dose or experienced other mistakes involving their medications, according to a new study supported in part by HHS' Agency for Healthcare Research and Quality through its Centers for Education and Research on Therapeutics program.

1 Jan 2009

VistaGen, WARF sign license agreement for human embryonic stem cell technology

VistaGen Therapeutics and the Wisconsin Alumni Research Foundation (WARF) have signed a license for human embryonic stem cell patents for the development and commercialization of stem cell-based research tools.

18 Dec 2008

Prozac enhances effectiveness of anti-cancer drug

Prozac is regularly prescribed to ease the emotional pain of patients who are being treated for cancer.

18 Dec 2008

Levels of two proteins impact survival in ovarian cancer

Levels of two proteins in a woman's ovarian cancer are strongly associated with her likelihood of survival, a research team led by scientists at The University of Texas M. D. Anderson Cancer Center reports in the Dec. 18 issue of the New England Journal of Medicine.

17 Dec 2008

Abbott starts trial of 2.25 mm stent system

Abbott has announced the start of SPIRIT Small Vessel, a clinical trial evaluating a 2.25 mm size of the XIENCE V Everolimus Eluting Coronary Stent System.

17 Dec 2008

Researchers find brain's reward and stress signaling circuits are intertwined in complex ways

Vanderbilt University Medical Center investigators have now discovered a functional link between reward and stress. They found that dopamine - the brain's chief reward signal - works through corticotrophin-releasing factor (CRF) - the brain's main stress signal - to increase the activity of a brain region involved in addiction relapse.

16 Dec 2008

Discovery of new way a man can transmit the HIV virus to a woman

Scientists had long believed that the normal lining of the female vaginal tract was an effective barrier to invasion of the HIV virus during sexual intercourse. They thought the large HIV virus couldn't penetrate the tissue.

16 Dec 2008

Trans-splicing therapy for spinal muscular atrophy closer to clinical use

Spinal muscular atrophy, a neurodegenerative disorder that causes the weakening of muscles, is the leading cause of infant death and occurs in 1 in 6,000 live births.

16 Dec 2008

Mucosal lining of the female genital tract no barrier to HIV sexual transmission

Contrary to a widely-held assumption about heterosexual transmission of HIV, the normal mucosal lining of the female genital tract is not a foolproof barrier to viral penetration, scientists at the Northwestern University School of Medicine in Chicago report at the American Society for Cell Biology (ASCB) 48th Annual Meeting, Dec. 13-17, 2008 in San Francisco.

16 Dec 2008

Alzheimer's researcher explores the variety of animal models now being used in research

Very few species spontaneously develop the cognitive, behavioral and neuropathological symptoms of Alzheimer's disease (AD), yet AD research must progress at a more rapid pace than the rate of human aging.

15 Dec 2008

Gene therapy used to treat periodontal disease

Scientists at the University of Michigan have shown that gene therapy can be used to successfully stop the development of periodontal disease, the leading cause of tooth loss in adults.

12 Dec 2008

Pralatrexate shows promise for T-Cell lymphoma

Preliminary results of a pivotal Phase 2 clinical trial of pralatrexate (PDX), a drug that partially works by mimicking folic acid, showed a complete or partial response in 27 percent of patients with recurrent or resistant peripheral T-cell lymphoma (PTCL).

10 Dec 2008

Potential breakthrough for T-cell lymphoma

10 Dec 2008

Intralytix awarded U.S. patent for bacteriophage treatment of colonization by pathogenic bacteria

Intralytix, Inc., announced today that it has been issued a patent by the U.S. Patent & Trademark Office covering the use of bacteriophages to reduce the risk of bacterial infection in persons colonized with pathogenic bacteria including MRSA.

10 Dec 2008

Alnylam Pharmaceuticals update on Kreutzer-Limmer patent estate

Alnylam Pharmaceuticals, Inc. has announced that the European Patent Office (EPO) has ruled in favor of the Appellants in oral proceedings before the Board of Appeals related to the '623 (EP 1144623) patent in its Kreutzer-Limmer patent estate.

10 Dec 2008

Cytori reports benefit of adipose-derived regenerative cells in spinal disc model

Cytori Therapeutics, Inc. reported preclinical study results, which demonstrate the potential benefit of adipose-derived stem and regenerative cells (ADRCs) for the treatment of damaged intervertebral discs, evidenced by significantly increased disc tissue density and disc-specific extracellular matrix components at 12-months post treatment in a large animal model.

8 Dec 2008

Dismissed leukemia drug flavopiridol helps chronic lymphocytic leukemia patients

A drug once dismissed as ineffective in patients with chronic lymphocytic leukemia (CLL) has shown promising results in two phase I and II clinical trials, according to researchers at The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute.

8 Dec 2008

Allos Therapeutics announces results from phase 2 trial of Pralatrexate in peripheral T-cell lymphoma

Allos Therapeutics, Inc. has announced preliminary top line results from PROPEL, the Company's pivotal Phase 2 trial of pralatrexate (PDX) in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL), at the 50th Annual Meeting of the American Society of Hematology (abstract 261).

8 Dec 2008

Motor neurons derived from human embryonic stem cells provide insight into ALS

Two new research studies use motor neurons derived from human embryonic stem (hES) cells to demonstrate that multiple toxic pathways contribute to the devastating degeneration associated with Amyotrophic Lateral Sclerosis (ALS) and that protective therapeutics will need to oppose the disease on multiple fronts.

3 Dec 2008

Therapeutics News and Research

Laminin-111 shows potential for congenital muscular dystrophy

Medication errors among adults and children with cancer in the outpatient setting common

VistaGen, WARF sign license agreement for human embryonic stem cell technology

Prozac enhances effectiveness of anti-cancer drug

Levels of two proteins impact survival in ovarian cancer

Abbott starts trial of 2.25 mm stent system

Researchers find brain's reward and stress signaling circuits are intertwined in complex ways

Discovery of new way a man can transmit the HIV virus to a woman

Trans-splicing therapy for spinal muscular atrophy closer to clinical use

Mucosal lining of the female genital tract no barrier to HIV sexual transmission

Alzheimer's researcher explores the variety of animal models now being used in research

Gene therapy used to treat periodontal disease

Pralatrexate shows promise for T-Cell lymphoma

Potential breakthrough for T-cell lymphoma

Intralytix awarded U.S. patent for bacteriophage treatment of colonization by pathogenic bacteria

Alnylam Pharmaceuticals update on Kreutzer-Limmer patent estate

Cytori reports benefit of adipose-derived regenerative cells in spinal disc model

Dismissed leukemia drug flavopiridol helps chronic lymphocytic leukemia patients

Allos Therapeutics announces results from phase 2 trial of Pralatrexate in peripheral T-cell lymphoma

Motor neurons derived from human embryonic stem cells provide insight into ALS

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News